login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
APOGEE THERAPEUTICS INC (APGE) Stock News
NASDAQ:APGE -
US03770N1019
-
Common Stock
36.37
USD
-0.25 (-0.68%)
Last: 8/29/2025, 8:06:34 PM
36.37
USD
0 (0%)
After Hours:
8/29/2025, 8:06:34 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
APGE Latest News, Press Relases and Analysis
All
Press Releases
22 days ago - By: Apogee Therapeutics
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results
22 days ago - By: Apogee Therapeutics
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results
a month ago - By: Yahoo Finance
Apogee Therapeutics, Inc. (APGE) Soars on Promising Phase 2 Results for Atopic Dermatitis Drug
2 months ago - By: Yahoo Finance
- Mentions:
GS
EXAS
BTIG Raises PT on Apogee Therapeutics (APGE) to $115 From $100, Keeps a Buy Rating
2 months ago - By: Benzinga
- Mentions:
PAHC
Top 2 Health Care Stocks That May Plunge This Month
2 months ago - By: Yahoo Finance
- Mentions:
MTSR
JPM
Metsera (MTSR) Presented at the 85th Scientific Sessions of the American Diabetes Association
2 months ago - By: Yahoo Finance
- Mentions:
JPM
Canaccord Genuity Reiterated a Buy Rating on Apogee Therapeutics (APGE)
2 months ago - By: Yahoo Finance
- Mentions:
PEP
Apogee Therapeutics (APGE) Falls 17%, Positive Trial Results Fail to Impress Investors
2 months ago - By: Benzinga
- Mentions:
RUN
NDRA
HUMA
PROK
...
Gold Falls 1%; ProKidney Shares Spike Higher
2 months ago - By: Yahoo Finance
- Mentions:
PEP
RGC
GFS
GlobalFoundries Stock Pops on AI Chip Designer Acquisition
2 months ago - By: Investor's Business Daily
- Mentions:
LLY
SNY
REGN
Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot
2 months ago - By: Apogee Therapeutics
Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis
2 months ago - By: Apogee Therapeutics
Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis
2 months ago - By: Apogee Therapeutics
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
2 months ago - By: Apogee Therapeutics
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
3 months ago - By: Apogee Therapeutics
Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference
3 months ago - By: Apogee Therapeutics
Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference
3 months ago - By: Zacks Investment Research
Wall Street Analysts Think Apogee Therapeutics Inc. (APGE) Could Surge 132.72%: Read This Before Placing a Bet
4 months ago - By: Apogee Therapeutics
Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results
4 months ago - By: Apogee Therapeutics
Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results
4 months ago - By: Apogee Therapeutics
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma
4 months ago - By: Apogee Therapeutics
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma
4 months ago - By: Apogee Therapeutics
Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference
4 months ago - By: Apogee Therapeutics
Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference
Please enable JavaScript to continue using this application.